Molecular and pathologic insights from latent HIV-1 infection in the human brain
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 14, 2012
- Accepted in final form November 29, 2012
- First Published March 13, 2013.
Article Versions
- Previous version (March 13, 2013 - 13:02).
- You are viewing the most recent version of this article.
Author Disclosures
- Paula Desplats, PhD,
- Wilmar Dumaop, BS,
- David Smith, MD,
- Anthony Adame, BS,
- Ian Everall, PhD,
- Scott Letendre, MD,
- Ronald Ellis, MD, PhD,
- Mariana Cherner, PhD,
- Igor Grant, MD and
- Eliezer Masliah, MD
- Paula Desplats, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
UCSD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wilmar Dumaop, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Smith, MD,
Pfizer Scientific Board for HIV medications 2008
NONE
NONE
editorial advisory boardThe Open AIDS Journal 2006 to presentThe Open Infectious Diseases Journal 2008 to present
NONE
NONE
NONE
Consultant and Board MemberSymmunity LLC
NONE
NONE
NONE
NONE
The investigator is supported by National Institutes ofHealth grants MH083552, AI077304, AI69432, MH62512,AI27670, AI38858, AI43638, AI43752, AI047745, UCSD Centersfor AIDS Research Viral Pathogenesis Core (AI36214)and HIVInfection of the San Diego Veterans Affairs HealthcareSystem (10-92-035) from 2007 to present.
NONE
NONE
Symmunity LLC
NONE
NONE
NONE
NONE
NONE
- Anthony Adame, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ian Everall, PhD,
Abbott Laboratories Pte Ltd.
NONE
Abbott Laboratories Pte Ltd., Commercial, honorariumAstraZeneca, Commercial, honorarium
Molecular PsychiatryTranslational PsychiatryJournal of VirologyHIV/AIDS - research adn Palliative CareNeurobevioral HIV Medicine
Detection of biomarkers for neuropsychiatric disorders, US20080261218A method comprising: performing a statistical analysis ona first set of gene data expressed in brain tissueobtained from a first control set not having aneuropsychiatric disorder and a second set of gene dataexpressed in central nervous system tissue obtained from afirst set of individuals having a neuropsychiatricdisorder to identify a first set of one or moredifferentially expressed genes; performing a statisticalanalysis on a third set of gene data expressed in bloodobtained from a second control set not having aneuropsychiatric disorder and a fourth set of gene dataexpressed in blood obtained from a second set ofindividuals having a neuropsychiatric disorder to identifya second set of one or more differentially expressedgenes; and comparing the first set of one or moredifferentially expressed genes to the second set of one ormore differentially expressed genes to identify a commonset of one or more differentially expressed genes.
Neurology of AIDS, 3rd Edition, OUP 2012
NONE
NONE
NONE
NONE
NONE
Abbott Laboratories Pte Ltd.
National Health and Medical Research Council, AustraliaCommonwealth Government of Australia
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Scott Letendre, MD,
(1) GlaxoSmithKline, 2011(2) Merck & Co., Inc., 2012
NONE
(1) Lucid Group UK, Speaker Honorarium(2) Stratagen, Speaker Honorarium
NONE
NONE
NONE
NONE
Merck & Co., Inc.
NONE
NONE
NONE
(1) GlaxoSmithKline, Paid to the University of California(2) Merck & Co., Inc., Paid to the University of California(3) Tibotec/Janssen, Paid to the University of California
(1) NIH, U01 MH083506, consultant, 2011, 2012(2) NIH, R01 MH58076, co-investigator, 2011, 2012(3) NIH, P01 DA12065, co-investigator, 2011, 2012(4) NIH, R01 MH73433, co-investigator, 2011, 2012(5) NIH, N01 MH22005, co-investigator, 2011, 2012(6) NIH, P30 MH62512, co-investigator, 2011, 2012(7) NIH, R01 MH78748, co-investigator, 2011, 2012(8) NIH, R21 MH85610, principal investigator, 2011, 2012(9) NIH, R01, MH92225, principal investigator, 2011, 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ronald Ellis, MD, PhD,
NONE
NONE
Abbott International, speaker honoraria
Journal of Neuroimmune Pharmacology, Editorial Advisory Board, 2007-2010
NONE
NONE
NONE
NeurogesX, Inc. - Consultant fee for FDA Advisory panel
NONE
NONE
NONE
NONE
(1) NIH, P30 MH62512, Co-investigator, 2010-2015 (2) NIH, N01 HHSN271201000036C, Co-investigator, 2010-2015(3) NIH, P50 DA26306, Co-investigator, 2009-2014(4) NIH, R01 MH095621, Co-investigator, 2011-2016 (5) NIH, U01 MH83506, Co-investigator, 2008-2013(6) NIH, R01 MH83552, Co-investigator, 2008-2013(7) NIH, R01 MH085608, Co-investigator, 2009-2013(8) NIH, R01 MH94159, Co-investigator, 2011-2016
NONE
NONE
NONE
NONE
NONE
NONE
Abbott Laboratories, stock held by spouseJohnson and Johnson, stock held by spouse
NONE
- Mariana Cherner, PhD,
NONE
NONE
travel to the annual meeting of the InternationalNeuropsychological Society as Chair of a Society committee
Journal of the International Neuropsychological Society,member of editorial board, 2004-2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH, MH81482, PI, 2007-present(2) NIH, DA27513, PI, 2009-2012(3) NIH, DA26334, PI, 2009-2012(4) NIH, MH62512, Co-I, 2006-present(5) NIH, DA26306, Co-I, 2009-present(6) NIH, MH58076, C0-I, 2006-2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Igor Grant, MD and
NONE
NONE
Abbott Pharmaceuticals speaker fee
(1)Journal of the International NeuropsychologicalSociety, Associate Editor, 2002-2004, (2) Journal ofNeurovirology, Associate Editor, 2002-present
NONE
NONE
NONE
NONE
Abbott Pharmaceuticals
NONE
NONE
NONE
(1) NIDA, DA26306, PI, 2009-present, (2) NIMH, MH83506,PI, 2002-present, (3) NIA, AG15301, PI, 2002-present, (4)NIMH, HHSN271201000036C, PI, 2010-present, (5) NIMH,HHSN271201000030C, PI, 2010-present, (6) NIMH, MH62512,Co-I, 2011-present, (7) NIMH, MH78748, Co-I, 2007-present,(8) NIMH, MH83552, Co-I, 2008-present, (9) NIMH, MH094159,Co-I, 2011-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eliezer Masliah, MD
NONE
NONE
EVER Pharma and NPT sponsored travel to international scientific meeting
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Neotope Biosciences, NPT, Neurophage
NIH NIA AG5131, AG18440, MH062962, AG043384
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neurosciences (P.D., A.A., R.E., E.M.), Pathology (W.D., E.M.), Medicine (D.S., S.L.), and Psychiatry (I.E., M.C., I.G.), University of California San Diego, La Jolla. Dr. Everall is currently affiliated with the Department of Psychiatry, University of Melbourne, Melbourne, Australia.
- Correspondence to Dr. Masliah: emasliah{at}ucsd.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.